Inhaled Technosphere® Insulin
MannKind Corporation has announced that it has initiated patient enrollment in its pivotal phase 3 safety trial of inhaled Technosphere® Insulin (TI) in the United States. However the time for the drug to hit the market is uncertain.
About Technosphere® Insulin
The MannKind inhaled insulin delivery system consists of a proprietary dry powder Technosphere® formulation of insulin that is inhaled into the deep lung using MannKind Corporation’s proprietary MedTone® inhaler, which utilizes single-use, disposable, plastic cartridges containing Technosphere® Insulin powder.
The inhaler is light, easy to use, and fits in the palm of the patient’s hand, which is believed to facilitate patient compliance.
Technosphere Insulin is stable for at least 18 months under refrigerated conditions and for at least two months at room temperature, which is equivalent to or surpasses commercially available insulin products.
The combination of Technosphere® Insulin’s unique performance characteristics including the rapid transfer of the insulin into the blood and the significantly higher bioavailability, along with the convenience and ease of use of the MedTone® inhaler, may have the potential to change the way diabetes is treated.
Reference - Medical News Today, Mannkind
Powered by MightyAdsense
